Introduction The primary systemic light chain amyloidosis(pAL) is a hematologic malignancy characterized by progressive organ dysfunc- tion. Numerous studies have demonstrated that cardiac involvement significantly impacts patient prognosis, surpassing the effects of other organ involvement and serving as the leading cause of mortality. In order to achieve profound hematologic response in AL patients with cardiac involvement, several investigations have confrmed that rapid and deep hematologic response correlates closely with improved survival rates. In order to enhance our understanding of the treatment effective- ness for AL patients with cardiac involvement, the authors conducted a comprehensive analysis of 16 patients and provided an overview of their overall treatment approach. The majority of these 16 cases involved patients with advanced cardiac amyloidosis.